Osprey Private Wealth LLC Buys 2,780 Shares of Thermo Fisher Scientific Inc. $TMO

Osprey Private Wealth LLC boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 19,140 shares of the medical research company’s stock after acquiring an additional 2,780 shares during the quarter. Thermo Fisher Scientific accounts for about 3.2% of Osprey Private Wealth LLC’s portfolio, making the stock its 9th biggest holding. Osprey Private Wealth LLC’s holdings in Thermo Fisher Scientific were worth $11,091,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Thermo Fisher Scientific by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock valued at $19,778,774,000 after purchasing an additional 288,296 shares in the last quarter. Capital World Investors lifted its holdings in Thermo Fisher Scientific by 7.4% in the 3rd quarter. Capital World Investors now owns 10,285,145 shares of the medical research company’s stock valued at $4,988,132,000 after purchasing an additional 706,572 shares in the last quarter. Franklin Resources Inc. lifted its holdings in Thermo Fisher Scientific by 21.0% in the 3rd quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company’s stock valued at $2,874,069,000 after purchasing an additional 1,028,125 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Thermo Fisher Scientific by 54.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company’s stock valued at $1,732,422,000 after purchasing an additional 1,262,967 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in Thermo Fisher Scientific by 5.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 3,087,666 shares of the medical research company’s stock valued at $1,789,148,000 after purchasing an additional 150,668 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on TMO shares. Robert W. Baird decreased their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Stifel Nicolaus decreased their price objective on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a report on Friday, April 24th. Morgan Stanley restated an “overweight” rating and issued a $620.00 price objective on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday. Finally, UBS Group reiterated a “neutral” rating and set a $615.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Buy” and an average price target of $619.65.

Insider Activity

In related news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 5,800 shares of company stock worth $2,963,544. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific News Summary

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Erste Group raised its FY2027 earnings estimate for Thermo Fisher, signaling slightly better long-term profit expectations for the company. Article
• Positive Sentiment: Thermo Fisher was included in CNBC’s “Final Trades,” which can reinforce investor interest and visibility in the stock. Article
• Neutral Sentiment: Thermo Fisher continues to be viewed as a key player in life sciences tools, and a new market note questioned whether the recent pullback makes the shares more attractive from a valuation standpoint. Article
• Neutral Sentiment: Proscia’s MedTech Breakthrough Award win mentioned Thermo Fisher among industry peers, but the item was focused on Proscia rather than a direct company-specific catalyst for TMO. Article
• Negative Sentiment: Wells Fargo cut its price target on Thermo Fisher from $675 to $615, which can weigh on sentiment even though the firm kept an overweight rating. Article

Thermo Fisher Scientific Stock Down 2.1%

Shares of NYSE TMO opened at $464.64 on Friday. The company has a 50 day simple moving average of $493.53 and a 200-day simple moving average of $546.70. The company has a market capitalization of $172.67 billion, a P/E ratio of 25.54, a P/E/G ratio of 2.06 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business’s revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were issued a $0.47 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date was Friday, March 13th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.